VTGN News and Press, Vistagen Therapeutics Inc.

NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategi...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X (SOXS) fell 12.9% to $3.24 on volume of 571,093,056 shares Baiya International Group Inc. (BIYA) rose 98.2% to $0.559 on volume of 395,783,956 shares LQR House Inc. (YHC) fell 91.5% to $0.079 on volu...

2026-06-30 14:12:09 ET Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder June 30, 2026 8:30 AM EDT... Read the full article on Seeking Alpha For further details see: Vistagen Therapeutics, Inc. (VTGN) D...

A look at the top 10 most actives in the United States Edible Garden AG Incorporated (EDBL) rose 90.1% to $0.310649 on volume of 202,720,280 shares INLIF LIMITED (INLF) fell 5.9% to $0.0621 on volume of 171,558,757 shares Baiya International Group Inc. (BIYA) rose 86.0% to $0.52455 on volum...

Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder Favorable safety...

2026-06-15 16:32:01 ET More on VistaGen Therapeutics Seeking Alpha’s Quant Rating on VistaGen Therapeutics Historical earnings data for VistaGen Therapeutics Financial information for VistaGen Therapeutics Read the full article on Seeking Alpha ...

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026 Achie...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company’s clinical program for fasedienol...

Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthca...

Dr. Angelov brings extensive industry experience across multiple therapeutic areas Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product cand...